Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study

Reuters12-09

Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study

Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104). The study is evaluating the addition of emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive (MRD+). The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD) following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42152) on December 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590349883?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590349883","market":"nz","top_or_hot":-1,"title":"Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104). The study is evaluating the addition of emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive (MRD+). The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD) following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42152) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuris Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104). The study is evaluating the addition of emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive (MRD+). The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD) following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42152) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLbNbjr1:1","article_id":"2590349883","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590349883","pubTimestamp":1765285262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia  triplet study . The study is evaluating the addition of emavusertib , an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive . The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients  achieved undetectable MRD  following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the origi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRIS":"居里"},"translate_title":"Curis报告在一线AML三联研究中检测不到MRD率为62.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRIS":0.9},"content_text":"Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study\n    \n\n        Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104). The study is evaluating the addition of emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive (MRD+). The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD) following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42152) on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590349883","isCrawlerRequest":true}